Biotech drugs from Naurex and Aptinyx come up short in FDA trials

A pair of new drugs developed locally fell flat in recent clinical trials, dealing a blow to Chicago’s fledgling biotech industry and one of its scientific stars.

In late January, Aptinyx’s treatment for diabetes-related pain failed a U.S. Food & Drug Administration Phase 2 study. This month, a depression drug developed by Aptinyx predecessor Naurex, which was acquired in 2015 by Irish drugmaker Allergan for $1.7 billion, flunked three Phase 3 studies.

The test results suggest neither...

What feeling does this article give you?

#hashtags to follow:

Chicago [+]    Aptinyx [+]    Drug Administration Phase 2 [+]    Naurex [+]    Allergan [+]    Phase 3 [+]   

More #news: